Welcome to MutualFunds.com. Please help us personalize your experience.
Your personalized experience is almost ready.
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission, we hope you enjoy your experience
18 Most Popular Mutual Fund Categories
View All Categories
15 Most Popular Fund Companies
View All Fund Companies
15 Most Popular Fund Company Quick Screens
View All Fund Company Quick Screens
Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.
Content focused on helping financial advisors build successful client relationships and grow their business.
Content geared towards helping financial advisors build better client portfolios.
Get insights on the industry trends and investment news from leading fund managers and experts.
Shauna O'Brien Mar 16, 2015
In the previous deal, Valeant offered to acquire the company for $158 per share, or $14.5 billion. The offer was increased after Endo International (ENDP) expressed interest in acquiring Salix for $175 per share, or $11 billion.
The adjusted deal has been approved by the Boards of Directors of both companies.
Last year, Valeant’s deal to acquire Allergan (AGN) fell through, and since then, VRX has been seeking alternative deals.
|PRGFX||T. Rowe Price Growth Stock||1.33%|
|SEEGX||JPMorgan Large Cap Growth Select||0.68%|
If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.
Receive email updates about best performers, news, CE accredited webcasts and more.